spacer
home > ebr > spring 2018 > sudden impact
PUBLICATIONS
European Biopharmaceutical Review

Sudden Impact

The development of biological therapeutics such as humanised antibodies has led to remarkable clinical benefits in many indications. Despite this success, the induction of anti-drug antibodies (ADAs) due to the potential immunogenicity of these therapeutics remains a significant challenge to the successful development of biotherapeutics.

The decades that followed the approval of the first biotherapeutic (Insulin, 1982) have seen a dramatic increase in both the number and rate of approvals. Biologics now account for over 30% of licensed pharmaceutical products and over 25% of the new drugs approved by The Center for Drug Evaluation and Research in 2015. For monoclonal antibodies (mAbs) alone, since the commercialisation of the first mAb in 1986, this class of product has increased significantly. By 2014, 47 mAb products had been approved in the US and Europe. At the current approval rate, it can be anticipated that approximately 70 mAb products will be on the market by 2020, with combined worldwide sales of nearly US$125 billion (1).

Despite this success, biologics can elicit immunological responses when administered to patients, which can affect their safety and efficacy. These side effects fall into two categories: pharmacological (largely predictable adverse reactions resulting from the interaction between the biologic and its target) and non-pharmacological. Non-pharmacological adverse events contain immunotoxicity, which includes both immuneresponseand non-immune response-mediated reactions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gary Bembridge is Senior Director of scientific affairs (immunology) at Abzena. Since joining the company in 2013, he has managed business development activities associated with immunological responses to biotherapeutics, ensuring that immunogenicity assessment and bespoke immunological studies are tailored to partners’ needs. Prior to this, Gary worked at Huntingdon Life Sciences (Envigo) as a Biopharmaceutical Product Development Manager and shared responsibility for designing safety studies and nonclinical development programmes for all biologics, providing scientific support and advice to the immunology department. He completed his PhD at the University of Bristol, UK, and the Department of Veterinary Medicine.

Dr Karen Hills is in marketing and business development at Abzena in Cambridge, UK. She is a consultant in pharma/biopharma business development and marketing. Since joining Abzena, Karen has focused on marketing across the areas of cell-line development, chemistry manufacturing, and immunology. Karen has a PhD in molecularb from Cambridge University, UK, and an MBA from the London Business School, UK. Her background includes sales, marketing, and business development for companies ranging from start-up biotech to Big Pharma.
spacer
Dr Gary Bembridge
spacer
spacer
spacer
Dr Karen Hills
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement